Role of exosomes in the pathogenesis, diagnosis, and treatment of central nervous system diseases

Y Fan, Z Chen, M Zhang - Journal of Translational Medicine, 2022 - Springer
Central nervous system (CNS) diseases, such as multiple sclerosis, Alzheimer's disease
(AD), and Parkinson's disease (PD), affect millions of people around the world. Great efforts …

Ultrasound-mediated blood–brain barrier opening: An effective drug delivery system for theranostics of brain diseases

J Wang, Z Li, M Pan, M Fiaz, Y Hao, Y Yan… - Advanced Drug Delivery …, 2022 - Elsevier
Blood-brain barrier (BBB) remains a significant obstacle to drug therapy for brain diseases.
Focused ultrasound (FUS) combined with microbubbles (MBs) can locally and transiently …

A nitric-oxide driven chemotactic nanomotor for enhanced immunotherapy of glioblastoma

H Chen, T Li, Z Liu, S Tang, J Tong, Y Tao… - Nature …, 2023 - nature.com
The major challenges of immunotherapy for glioblastoma are that drugs cannot target tumor
sites accurately and properly activate complex immune responses. Herein, we design and …

Cell–cell communication: new insights and clinical implications

J Su, Y Song, Z Zhu, X Huang, J Fan, J Qiao… - Signal Transduction and …, 2024 - nature.com
Multicellular organisms are composed of diverse cell types that must coordinate their
behaviors through communication. Cell–cell communication (CCC) is essential for growth …

[HTML][HTML] Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?

C Fu, L Yu, Y Miao, X Liu, Z Yu, M Wei - Acta Pharmaceutica Sinica B, 2023 - Elsevier
Peptide–drug conjugates (PDCs) are the next generation of targeted therapeutics drug after
antibody–drug conjugates (ADCs), with the core benefits of enhanced cellular permeability …

Drug conjugate-based anticancer therapy-Current status and perspectives

Y Yang, S Wang, P Ma, Y Jiang, K Cheng, Y Yu… - Cancer Letters, 2023 - Elsevier
Drug conjugates are conjugates comprising a tumor-homing carrier tethered to a cytotoxic
agent via a linker that are designed to deliver an ultra-toxic payload directly to the target …

Cell-penetrating and targeted peptides delivery systems as potential pharmaceutical carriers for enhanced delivery across the blood–brain barrier (BBB)

SM Ghorai, A Deep, D Magoo, C Gupta, N Gupta - Pharmaceutics, 2023 - mdpi.com
Among the challenges to the 21st-century health care industry, one that demands special
mention is the transport of drugs/active pharmaceutical agents across the blood–brain …

[HTML][HTML] The barrier and interface mechanisms of the brain barrier, and brain drug delivery

S Zhang, L Gan, F Cao, H Wang, P Gong, C Ma… - Brain Research …, 2022 - Elsevier
Three different barriers are formed between the cerebrovascular and the brain parenchyma:
the blood-brain barrier (BBB), the blood-cerebrospinal fluid barrier (BCSFB), and the …

Transferrin receptor 1 targeted nanomedicine for brain tumor therapy

J Li, Z Zhang, B Zhang, X Yan, K Fan - Biomaterials Science, 2023 - pubs.rsc.org
Achieving effective drug delivery to traverse the blood–brain barrier (BBB) and target tumor
cells remains the greatest challenge for brain tumor therapy. Importantly, the overexpressed …

Peptides as pharmacological carriers to the brain: promises, shortcomings and challenges

S Parrasia, I Szabò, M Zoratti… - Molecular …, 2022 - ACS Publications
Central nervous system (CNS) diseases are among the most difficult to treat, mainly
because the vast majority of the drugs fail to cross the blood-brain barrier (BBB) or to reach …